What Is Bioceres Crop Solutions Corp. (BIOX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bioceres Crop Solutions Corp.'s intrinsic value is estimated at a composite $0.76, showing conflicting signals at the current price of $0.34. While the average implied return is +123.9%, model disagreement is elevated with a gap of +552.9% between the most bullish and bearish estimates. The most optimistic model, FTNN, places fair value at $1.91 (+459.8%), while Markov DDM — the most conservative — estimates $0.02 (-93.1%). This +552.9% gap reflects genuine analytical uncertainty about Bioceres Crop Solutions Corp.'s intrinsic worth.
What Do the Models Say About BIOX?
4 of 13 models are currently active for BIOX. Of these, 2 models suggest upside while 2 models suggest overvaluation. See which stocks rank higher →
How Does BIOX Rank in Agricultural Chemicals?
Among 12 Agricultural Chemicals stocks, BIOX ranks #3 by Quality of Company score. CirclFi's QOC score of 8.3/10 evaluates 32 fundamental signals. A score of 8.3 places BIOX in the top tier.
Bioceres Crop Solutions Corp.'s positioning within the Agricultural Chemicals segment means that margin expansion trajectory plays an outsized role in fundamental analysis. The sector's unique characteristics — including aftermarket and services growth — shape both the opportunity set and risk profile.
Is BIOX a Value Trap?
CirclFi's Value Trap algorithm assigns BIOX a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
4 of 13 models are active for Bioceres Crop Solutions Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Bioceres Crop Solutions Corp. earns a quality score of 8.3/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +552.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BIOX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BIOX's 4 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad